Literature DB >> 12171581

Chemotherapy of Chagas' disease: status and new developments.

Hugo Cerecetto1, Mercedes González.   

Abstract

Chagas' disease is a major parasitic problem in developing countries in Central and South America. Chemotherapy for such disease is still insufficient and not effective in its chronic part. Many efforts have been made in recent years to know more about possible new biochemical targets to design new selective drugs. This paper reviews old therapeutic approaches -Nifurtimox, Benznidazole and related compounds- and the latest rationally developed drugs that prove to be active against different parasitic forms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171581     DOI: 10.2174/1568026023393066

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  13 in total

1.  Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole.

Authors:  S Radhika Prathalingham; Shane R Wilkinson; David Horn; John M Kelly
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

2.  A comparison of toxicity and toxicokinetics in rats and dogs following twenty-eight-day, repeat-dose oral administration of nifurtimox.

Authors:  Ye Li; Tian-Tian Liu; Hong-Tao Jin; Piao-Piao Zhang; Dan Qin; Qian-Qian Zhang; Wen-Tao Wu; Cui-Ping Yang; Ai-Ping Wang
Journal:  Toxicol Res (Camb)       Date:  2017-05-17       Impact factor: 3.524

3.  Experimental chemotherapy in paracoccidioidomycosis using ruthenium NO donor.

Authors:  Wander Rogério Pavanelli; Jean Jerley Nogueira da Silva; Carolina Panis; Thiago Mattar Cunha; Ivete Conchon Costa; Maria Claudia Noronha Dutra de Menezes; Francisco José de Abreu Oliveira; Luiz Gonzaga de França Lopes; Rubens Cecchini; Fernando de Queiroz Cunha; Maria Angélica Ehara Watanabe; Eiko Nakagawa Itano
Journal:  Mycopathologia       Date:  2011-03-25       Impact factor: 2.574

4.  Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole.

Authors:  Annamaria Buschini; Lisa Ferrarini; Susanna Franzoni; Serena Galati; Mirca Lazzaretti; Francesca Mussi; Cristina Northfleet de Albuquerque; Tânia Maria Araújo Domingues Zucchi; Paola Poli
Journal:  J Parasitol Res       Date:  2009-10-21

5.  Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors.

Authors:  Jean Jerley N Silva; Wander R Pavanelli; José Clayston M Pereira; João S Silva; Douglas W Franco
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

6.  Anti-Trypanosoma cruzi and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives.

Authors:  Juan Carlos Villalobos-Rocha; Luvia Sánchez-Torres; Benjamín Nogueda-Torres; Aldo Segura-Cabrera; Carlos A García-Pérez; Virgilio Bocanegra-García; Isidro Palos; Antonio Monge; Gildardo Rivera
Journal:  Parasitol Res       Date:  2014-04-02       Impact factor: 2.289

7.  In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors.

Authors:  J J N Silva; A L Osakabe; W R Pavanelli; J S Silva; D W Franco
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

8.  Evaluation of genotoxic effects of new molecules with possible trypanocidal activity for Chagas disease treatment.

Authors:  Francisco V C Mello; Alcione S Carvalho; Mônica M Bastos; Nubia Boechat; Claudia A F Aiub; Israel Felzenszwalb
Journal:  ScientificWorldJournal       Date:  2013-11-07

9.  Biogenic trypanocidal sesquiterpenes: lead compounds to design future trypanocidal drugs - a mini review.

Authors:  Soodabeh Saeidnia; Ahmad Reza Gohari; Azita Haddadi
Journal:  Daru       Date:  2013-05-15       Impact factor: 3.117

10.  Unraveling the differences of the hydrolytic activity of Trypanosoma cruzi trans-sialidase and Trypanosoma rangeli sialidase: a quantum mechanics-molecular mechanics modeling study.

Authors:  Juan A Bueren-Calabuig; Gustavo Pierdominici-Sottile; Adrian E Roitberg
Journal:  J Phys Chem B       Date:  2014-05-21       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.